Company: ZLAB
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001628280-25-008409
Chunk: 250

Company: Zai Lab Ltd
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 250
---

Trust for Life: Our sustainability strategy, which includes three pillars: improve human health, create better outcomes, and act right now with ethical business practices and strong governance

Turning Point: Turning Point Therapeutics, Inc. 

U.S.: United States

U.S. GAAP: Generally Accepted Accounting Principles in the United States

VABP: Ventilator-associated bacterial pneumonia

Vertex: Vertex Pharmaceuticals Inc.

VIEs: Variable interest entities

VYVGART: The brand name for the IV formulation of efgartigimod

VYVGART Hytrulo: The brand name for the SC formulation of efgartigimod

XACDURO (SUL-DUR): A combination of a beta-lactam antibiotic (sulbactam) and beta-lactamase inhibitor (durlobactam) 

Zai Lab: Zai Lab Limited, holding company, and its subsidiaries on a consolidated basis

Zai Lab Limited: Zai Lab Limited, a holding company

-101-

Zai Lab Shanghai: Zai Lab (Shanghai) Co., Ltd., a wholly-owned subsidiary of the Company

Zai Lab Suzhou: Zai Lab (Suzhou) Co., Ltd., a wholly-owned subsidiary of the Company

ZEJULA (Niraparib): An orally administered PARP 1/2 inhibitor

ZL-1102: An early clinical stage human VH antibody fragment that binds to IL-17

ZL-1218: An early clinical stage humanized anti-CCR8 IgG1 monoclonal antibody

ZL-1310: An early-stage next generation DLL3 ADC

ZL-1503: A pre-clinical IL-13 / IL-31 bi-specific antibody

1L: First line

2L: Second line

4L: Fourth Line

2015 Plan: Zai Lab Limited 2015 Omnibus Equity Incentive Plan, as amended

2017 Plan: Zai Lab Limited 2017 Equity Incentive Plan

2022 Plan: Zai Lab Limited 2022 Equity Incentive Plan

2024 Annual Report: Annual Report on Form 10-K for the year ended December 31, 2024

2024 Plan: Zai Lab Limited 2024 Equity Incentive Plan

2025 Proxy Statement: Our definitive proxy statement pursuant to Regulation 14A to be filed with the SEC not later than 120 days after the close of our fiscal